Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Chronic human colchicine myopathy].

T Iwatsubo1, Y Ishige, N Nukina

  • 1Department of Neurology, Institute of Brain Research, Faculty of Medicine, University of Tokyo.

Rinsho Shinkeigaku = Clinical Neurology
|September 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Japanese Subgroup Analyses from EMERGE and ENGAGE, Phase 3 Clinical Trials of Aducanumab in Patients with Early Alzheimer's Disease.

The journal of prevention of Alzheimer's disease·2024
Same author

Usability of a Web-Based Registry for Preclinical Alzheimer's Disease: Implications from a Cross-Sectional Online Survey.

The journal of prevention of Alzheimer's disease·2024
Same author

Editorial: Clinical Implementation of Lecanemab: Challenges, Questions and Solutions.

The journal of prevention of Alzheimer's disease·2023
Same author

Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab.

The journal of prevention of Alzheimer's disease·2023
Same author

Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.

The journal of prevention of Alzheimer's disease·2022
Same author

Therapeutic Targets for Alzheimer's Disease: Amyloid Vs. Non-Amyloid. Where Does Consensus Lie Today? An CTAD Task Force Report.

The journal of prevention of Alzheimer's disease·2022

Colchicine-induced myopathy can occur in patients with renal dysfunction, even at daily doses. Prompt discontinuation of colchicine led to recovery of muscle strength and normalization of creatine kinase levels.

Area of Science:

  • Neurology
  • Toxicology
  • Pathology

Background:

  • Colchicine is a common medication for gout.
  • Renal dysfunction can affect drug metabolism and excretion.

Observation:

  • A 65-year-old man with gout and renal dysfunction developed progressive proximal limb weakness after increasing daily colchicine dosage.
  • Neurological examination revealed proximal muscle weakness, hyporeflexia, and sensory disturbances.
  • Elevated creatine kinase and creatinine levels, along with myogenic changes on electromyography, were noted.

Findings:

  • Muscle biopsy showed characteristic changes including rimmed vacuoles, moth-eaten and targetoid fibers, and lysosomal accumulation.
  • These histological findings are indicative of a toxic myopathy.
  • Discontinuation of colchicine resulted in clinical and biochemical recovery.

Related Experiment Videos

Implications:

  • Colchicine myopathy can mimic other neuromuscular disorders like polymyositis.
  • Caution is advised when prescribing daily colchicine, especially in patients with impaired renal function.
  • Awareness of this potential adverse effect is crucial for timely diagnosis and management.